Activities of ceftobiprole and other cephalosporins against extracellular and intracellular (THP-1 macrophages and keratinocytes) forms of methicillin-susceptible and methicillin-resistant Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 6, 2009, Pages 2289-2297

  Lemaire, Sandrine ^a   Glupczynski, Youri ^b   Duval, Valérie ^c   Joris, Bernard ^c   Tulkens, Paul M ^a   Van Bambeke, Françoise ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^c UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; BOCILLIN FL; CARBAPENEM DERIVATIVE; CEFALEXIN; CEFOXITIN; CEFTOBIPROLE; CEFTRIAXONE; CEFUROXIME; OXYTETRACYCLINE; PENICILLIN BINDING PROTEIN 2A; PENICILLIN DERIVATIVE; PENICILLIN V; UNCLASSIFIED DRUG;

ACIDITY; ACYLATION; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BINDING COMPETITION; CONFORMATIONAL TRANSITION; DRUG POTENCY; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; IN VITRO STUDY; INOCULATION; KERATINOCYTE; MACROPHAGE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; CELL LINE; CEPHALOSPORINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROGEN-ION CONCENTRATION; KERATINOCYTES; MACROPHAGES; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; PHAGOCYTOSIS; RIBONUCLEOPROTEINS; SACCHAROMYCES CEREVISIAE PROTEINS; STAPHYLOCOCCUS AUREUS;

EID: 67049168801     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01135-08     Document Type: Article

References (43)

1. Alexander, E. H., and M. C. Hudson. 2001. Factors influencing the internalization of Staphylococcus aureus and impacts on the course of infections in humans. Appl. Microbiol. Biotechnol. 56:361-366.
2. Amsler, K. M., T. A. Davies, W. Shang, M. R. Jacobs, and K. Bush. 2008. In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections. Antimicrob. Agents Chemother. 52:3418-3423.
3. Anderson, S. D., and J. G. Gums. 2008. Ceftobiprole: an extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin. Ann. Pharmacother. 42:806-816.
4. Angehrn, P., P. Hebeisen, I. Heinze-Krauss, M. Page, and V. Runtz. June 1998. Preparation of vinylpyrrolidine derivatives of cephalosporins with basic substituents, p. 1-54. European Union patent no. EP0849269.
5. Bamberger, D. M. 2007. Bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: the potential role of daptomycin. Ther. Clin. Risk Manag. 3:675-684.
6. Barcia-Macay, M., S. Lemaire, M. P. Mingeot-Leclercq, P. M. Tulkens, and F. Van Bambeke. 2006. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 58:1177-1184.
7. Barcia-Macay, M., C. Seral, M. P. Mingeot-Leclercq, P. M. Tulkens, and F. Van Bambeke. 2006. Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob. Agents Chemother. 50:841-851.
8. Dancer, S. J. 2008. The effect of antibiotics on methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 61:246-253.
9. de Lencastre, H., D. Oliveira, and A. Tomasz. 2007. Antibiotic resistant Staphylococcus aureus: a paradigm of adaptive power. Curr. Opin. Microbiol. 10:428-435.
10. Deresinski, S. C. 2008. The efficacy and safety of ceftobiprole in the treatment of complicated skin and skin structure infections: evidence from 2 clinical trials. Diagn. Microbiol. Infect. Dis. 61:103-109.
11. Fuda, C., D. Hesek, M. Lee, W. Heilmayer, R. Novak, S. B. Vakulenko, and S. Mobashery. 2006. Mechanistic basis for the action of new cephalosporin antibiotics effective against methicillin- and vancomycin-resistant Staphylococcus aureus. J. Biol. Chem. 281:10035-10041.
12. Gaze, W., C. O'Neill, E. Wellington, and P. Hawkey. 2008. Antibiotic resistance in the environment, with particular reference to MRSA. Adv. Appl. Microbiol. 63:249-280.
13. Gee, K. R., H. C. Kang, T. I. Meier, G. Zhao, and L. C. Blaszcak. 2001. Fluorescent Bocillins: synthesis and application in the detection of penicillin-binding proteins. Electrophoresis 22:960-965. (Pubitemid 32318417)
14. Graves-Woodward, K., and R. F. Pratt. 1998. Reaction of soluble penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus with betalactams and acyclic substrates: kinetics in homogeneous solution. Biochem. J. 332(Pt 3):755-761. (Pubitemid 28306702)
15. Hebeisen, P., I. Heinze-Krauss, P. Angehrn, P. Hohl, M. G. Page, and R. L. Then. 2001. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 45:825-836.
16. Kluytmans-Vandenbergh, M. F., and J. A. Kluytmans. 2006. Community-acquired methicillin-resistant Staphylococcus aureus: current perspectives. Clin. Microbiol. Infect. 12(Suppl. 1):9-15.
17. Lemaire, S., C. Fuda, F. Van Bambeke, P. M. Tulkens, and S. Mobashery. 2008. Restoration of susceptibility of methicillin-resistant Staphylococcus aureus to beta-lactam antibiotics by acidic pH: role of penicillin-binding protein PBP 2a. J. Biol. Chem. 283:12769-12776.
18. Lemaire, S., A. Olivier, F. Van Bambeke, P. M. Tulkens, P. C. Appelbaum, and Y. Glupczynski. 2008. Restoration of susceptibility of intracellular methicillin-resistant Staphylococcus aureus to beta-lactams: comparison of strains, cells, and antibiotics. Antimicrob. Agents Chemother. 52:2797-2805.
19. Lemaire, S., F. Van Bambeke, M. P. Mingeot-Leclercq, Y. Glupczynski, and P. M. Tulkens. 2007. Role of acidic pH in the susceptibility of intraphagocytic methicillin-resistant Staphylococcus aureus strains to meropenem and cloxacillin. Antimicrob. Agents Chemother. 51:1627-1632.
20. Lemaire, S., F. Van Bambeke, M. P. Mingeot-Leclercq, and P. M. Tulkens. 2005. Activity of three β-lactams (ertapenem, meropenem and ampicillin) against intraphagocytic Listeria monocytogenes and Staphylococcus aureus. J. Antimicrob. Chemother. 55:897-904.
21. Leonard, F. C., and B. K. Markey. 2008. Meticillin-resistant Staphylococcus aureus in animals: a review. Vet. J. 175:27-36. (Pubitemid 351187517)
22. Lovering, A., F. Danel, M. G. P. Page, and N. J. Strynadka. 2006. Mechanism of action of ceftobiprole: structural basis for the anti-MRSA activity, abstr. 1506. Program Abstr. 16th Eur. Conf. Clin. Microbiol. Infect.
23. Lowy, F. D. 2000. Is Staphylococcus aureus an intracellular pathogen? Trends Microbiol. 8:341-343.
24. Mempel, M., C. Schnopp, M. Hojka, H. Fesq, S. Weidinger, M. Schaller, H. C. Korting, J. Ring, and D. Abeck. 2002. Invasion of human keratinocytes by Staphylococcus aureus and intracellular bacterial persistence represent haemolysin-independent virulence mechanisms that are followed by features of necrotic and apoptotic keratinocyte cell death. Br. J. Dermatol. 146:943-951.
25. Mouton, J. W., A. Schmitt-Hoffmann, S. Shapiro, N. Nashed, and N. C. Punt. 2004. Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141. Antimicrob. Agents Chemother. 48:1713-1718.
26. Noel, G. J., K. Bush, P. Bagchi, J. Ianus, and R. S. Strauss. 2008. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin. Infect. Dis. 46:647-655.
27. Page, M. G. 2007. Emerging cephalosporins. Expert Opin. Emerg. Drugs 12:511-524.
28. Pantosti, A., A. Sanchini, and M. Monaco. 2007. Mechanisms of antibiotic resistance in Staphylococcus aureus. Future Microbiol. 2:323-334. (Pubitemid 47180928)
29. Preston, D. A., C. Y. Wu, L. C. Blaszczak, D. E. Seitz, and N. G. Halligan. 1990. Biological characterization of a new radioactive labeling reagent for bacterial penicillin-binding proteins. Antimicrob. Agents Chemother. 34:718-721.
30. Sabath, L. D., S. J. Wallace, and D. A. Gerstein. 1972. Suppression of intrinsic resistance to methicillin and other penicillins in Staphylococcus aureus. Antimicrob. Agents Chemother. 2:350-355.
31. Sakoulas, G., and R. C. Moellering, Jr. 2008. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. Clin. Infect. Dis. 46(Suppl. 5):S360-S367.
32. Sandberg, A., J. H. R. Hessler, R. L. Skov, J. Blom, and N. Frimødt-Moller. 2009. Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model. Antimicrob. Agents Chemother. 53:1874-1883.
33. Seral, C., F. Van Bambeke, and P. M. Tulkens. 2003. Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. Antimicrob. Agents Chemother. 47:2283-2292.
34. Sinha, B., and M. Herrmann. 2005. Mechanism and consequences of invasion of endothelial cells by Staphylococcus aureus. Thromb. Haemost. 94: 266-277.
35. Stryjewski, M. E., and H. F. Chambers. 2008. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 46(Suppl. 5):S368-S377.
36. Tulkens, P. M. 1991. Intracellular distribution and activity of antibiotics. Eur. J. Clin. Microbiol. Infect. Dis. 10:100-106.
37. Utsui, Y., and T. Yokota. 1985. Role of an altered penicillin-binding protein in methicillin- and cephem-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 28:397-403.
38. Van Bambeke, F., M. Barcia-Macay, S. Lemaire, and P. M. Tulkens. 2006. Cellular pharmacodynamics and pharmacokinetics of antibiotics: current views and perspectives. Curr. Opin. Drug Discov. Dev. 9:218-230.
39. Villegas-Estrada, A., M. Lee, D. Hesek, S. B. Vakulenko, and S. Mobashery. 2008. Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA beta-lactam antibiotics. J. Am. Chem. Soc. 130:9212-9213.
40. Vonk, A. G., and C. M. Vandenbroucke-Grauls. 2007. Methicillin-resistant Staphylococcus aureus (MRSA) in the community. Ned. Tijdschr. Geneeskd. 151:401-407. (In Dutch.)
41. Wijaya, L., L. Y. Hsu, and A. Kurup. 2006. Community-associated methicillin-resistant Staphylococcus aureus: overview and local situation. Ann. Acad. Med. Singapore 35:479-486.
42. Zbinden, R., V. Punter, and A. von Graevenitz. 2002. In vitro activities of BAL9141, a novel broad-spectrum pyrrolidinone cephalosporin, against gram-negative nonfermenters. Antimicrob. Agents Chemother. 46:871-874.
43. Zhanel, G. G., A. Lam, F. Schweizer, K. Thomson, A. Walkty, E. Rubinstein, A. S. Gin, D. J. Hoban, A. M. Noreddin, and J. A. Karlowsky. 2008. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin. Am. J. Clin. Dermatol. 9:245-254.